Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
05:43pm, Monday, 08'th Sep 2025
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Brian Lian - President, CEO & Director Conference Ca
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
11:14am, Sunday, 07'th Sep 2025
The market was less than impressed with the top-line results from Viking Therapeutics' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the
Down 34%, Should You Buy the Dip on Viking Therapeutics?
04:10am, Friday, 05'th Sep 2025
Viking Therapeutics (VKTX -1.12%) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk do
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
11:31am, Tuesday, 02'nd Sep 2025
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
06:46pm, Friday, 29'th Aug 2025
Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.
Why Viking Therapeutics Stock Popped Nearly 4% Today
06:42pm, Thursday, 28'th Aug 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics.
Viking Therapeutics to Participate at Upcoming Investor Conferences
04:30pm, Thursday, 28'th Aug 2025
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
11:55am, Wednesday, 27'th Aug 2025
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)
10:00am, Wednesday, 27'th Aug 2025
This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around Federal
Viking Therapeutics: What's Next?
06:15am, Tuesday, 26'th Aug 2025
Viking Therapeutics (VKTX -0.69%) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2 resul
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
08:45am, Sunday, 24'th Aug 2025
Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter ha
Viking: Still On Track, But The Compass Needs Recalibration
06:57am, Saturday, 23'rd Aug 2025
Viking's oral VK2735 efficacy was strong, but tolerability issues and high discontinuation rates cloud its competitive edge in the obesity drug market. The market's perception of Viking shifted after
Here's Why Shares in Viking Therapeutics Crashed This Week
10:21am, Friday, 22'nd Aug 2025
Shares in Viking Therapeutics (VKTX 1.13%) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its lead
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
01:06pm, Thursday, 21'st Aug 2025
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?
05:24am, Thursday, 21'st Aug 2025
As of Aug. 20, shares of Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its oral
